Zealand increases its share capital as a consequence of exercise of employee warrants

Copenhagen, May 30, 2017 – Zealand Pharma (“Zealand”) has increased its share capital by a nominal amount of DKK 5,000 divided into 5,000 new shares with a nominal value of DKK 1 each. The increase is a consequence of the exercise of warrants granted under one of Zealand`s employee warrant programs. Employee warrant programs are part of Zealand`s incentive scheme, and each warrant gives the owner the right to subscribe for one new Zealand share at a pre specified price, the exercise price, in specific predefined time periods before expiration. For a more detailed description of Zealand`s warrant programs, see the company`s Articles of Association, which are available on the website: